In respect to OSA…
July 2021
IHL files an International patent application for IHL-42X based on interim analysis of the data from the phase 2b trial. The results were included in the patent application to support the claims.
And, they received ethics approval to commence an open label extension study for people who have experienced a benefit from IHL-42X.
December 2021
Dosing completed and the company immediately commenced preparation for a pre-IND meeting with FDA, targeting Q1, 2022.
Any of this sound negative to you? It sounds extremely positive to me.
- Forums
- ASX - By Stock
- IHL
- Ann: Quarterly Activities/Appendix 4C Cash Flow Report
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-18
-
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IHL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online